Clinical Trial Update: Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluated the maximum tolerated dose, safety, and efficacy of combining docetaxel and cisplatin with STI571 (imatinib) in non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• STI571 (imatinib) (imatinib)

Snippet

Sponsor: Duke University | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-09-15